全文获取类型
收费全文 | 402篇 |
免费 | 33篇 |
专业分类
435篇 |
出版年
2017年 | 6篇 |
2015年 | 7篇 |
2014年 | 6篇 |
2013年 | 23篇 |
2012年 | 7篇 |
2011年 | 7篇 |
2010年 | 4篇 |
2009年 | 7篇 |
2008年 | 8篇 |
2007年 | 7篇 |
2006年 | 8篇 |
2005年 | 7篇 |
2004年 | 8篇 |
2003年 | 12篇 |
2002年 | 4篇 |
2001年 | 6篇 |
2000年 | 6篇 |
1999年 | 13篇 |
1998年 | 14篇 |
1997年 | 7篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 13篇 |
1989年 | 8篇 |
1988年 | 8篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 7篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1976年 | 5篇 |
1975年 | 9篇 |
1974年 | 5篇 |
1973年 | 7篇 |
1972年 | 5篇 |
1971年 | 7篇 |
1970年 | 6篇 |
1968年 | 4篇 |
1967年 | 8篇 |
1966年 | 5篇 |
1954年 | 7篇 |
1952年 | 5篇 |
1945年 | 6篇 |
排序方式: 共有435条查询结果,搜索用时 15 毫秒
61.
C M Ogilvie 《BMJ (Clinical research ed.)》1978,1(6115):771-773
62.
63.
64.
65.
James G. Ogilvie Steven Van Belleghem Ryan Range Riccardo Papa Owen W. McMillan Mathieu Chouteau Brian A. Counterman 《Ecology and evolution》2021,11(24):18319
The evolution of mimicry in similarly defended prey is well described by the Müllerian mimicry theory, which predicts the convergence of warning patterns in order to gain the most protection from predators. However, despite this prediction, we can find great diversity of color patterns among Müllerian mimics such as Heliconius butterflies in the neotropics. Furthermore, some species have evolved the ability to maintain multiple distinct warning patterns in single populations, a phenomenon known as polymorphic mimicry. The adaptive benefit of these polymorphisms is questionable since variation from the most common warning patterns is expected to be disadvantageous as novel signals are punished by predators naive to them. In this study, we use artificial butterfly models throughout Central and South America to characterize the selective pressures maintaining polymorphic mimicry in Heliconius doris. Our results highlight the complexity of positive frequency‐dependent selection, the principal selective pressure driving convergence among Müllerian mimics, and its impacts on interspecific variation of mimetic warning coloration. We further show how this selection regime can both limit and facilitate the diversification of mimetic traits. 相似文献
66.
Daniel P. Mould Ulf Bremberg Allan M. Jordan Matthis Geitmann Alba Maiques-Diaz Alison E. McGonagle Helen F. Small Tim C.P. Somervaille Donald Ogilvie 《Bioorganic & medicinal chemistry letters》2017,27(14):3190-3195
A series of reversible inhibitors of lysine specific demethylase 1 (LSD1) with a 5-hydroxypyrazole scaffold have been developed from compound 7, which was identified from the patent literature. Surface plasmon resonance (SPR) and biochemical analysis showed it to be a reversible LSD1 inhibitor with an IC50 value of 0.23 µM. Optimisation of this compound by rational design afforded compounds with Kd values of <10 nM. In human THP-1 cells, these compounds were found to upregulate the expression of the surrogate cellular biomarker CD86. Compound 11p was found to have moderate oral bioavailability in mice suggesting its potential for use as an in vivo tool compound. 相似文献
67.
Daniel P. Mould Ulf Bremberg Allan M. Jordan Matthis Geitmann Alison E. McGonagle Tim C.P. Somervaille Gary J. Spencer Donald J. Ogilvie 《Bioorganic & medicinal chemistry letters》2017,27(20):4755-4759
As part of our ongoing efforts to develop reversible inhibitors of LSD1, we identified a series of 4-(pyrrolidin-3-yl)benzonitrile derivatives that act as successful scaffold-hops of the literature inhibitor GSK-690. The most active compound, 21g, demonstrated a Kd value of 22 nM and a biochemical IC50 of 57 nM. In addition, this compound displayed improved selectivity over the hERG ion channel compared to GSK-690, and no activity against the related enzymes MAO-A and B. In human THP-1 acute myeloid leukaemia cells, 21g was found to increase the expression of the surrogate cellular biomarker CD86. This work further demonstrates the versatility of scaffold-hopping as a method to develop structurally diverse, potent inhibitors of LSD1. 相似文献
68.
Barlaam B Acton DG Ballard P Bradbury RH Cross D Ducray R Germain H Hudson K Klinowska T Magnien F Ogilvie DJ Olivier A Ross HS Smith R Trigwell CB Vautier M Wright L 《Bioorganic & medicinal chemistry letters》2008,18(6):1799-1803
We have identified a new series of C-5 substituted indazolylaminoquinazolines as potent erbB2 kinase inhibitors. The lead compound 22 showed excellent in vitro potency, good physical properties, acceptable oral pharmacokinetics in rat and dog, and low human in vitro clearance. It showed at least equivalent activity dose for dose compared to lapatinib in various erbB2- or EGFR-driven xenograft models after chronic oral administration. 相似文献
69.
70.